<DOC>
	<DOCNO>NCT02982707</DOCNO>
	<brief_summary>A single oral dose BMS-986177administered subject mild hepatic impairment , moderate hepatic impairment healthy match subject evaluate pharmacokinetics , safety , tolerability subject</brief_summary>
	<brief_title>Single-dose Pharmacokinetics BMS-986177 Participants With Hepatic Impairment Compared Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>BMI 20.0 38.0 kg/m2 , inclusive Hepatic subject classify ChildPugh mild ( Class A ) ChildPugh moderate ( Class B ) significant change disease status past 6 month stable treatment regimen Healthy subject must clinically significant deviation normal medical history , physical exam , ECGs , vital sign clinical lab value Women must child bear potential male sexually active woman child bear potential must agree use acceptable contraception 92 day follow dose Evidence coagulopathy , prolong unexplained clinically significant bleeding , frequent unexplained bruising thrombus formation Use corticosteroid , nonsteroidal antiinflammatory compound , aspirin antiplatelet agent anticoagulant within 2 week dose Healthy subject must use tobacco history drug alcohol abuse within last 6 month Subjects must current recent ( within 3 month ) GI disease increase participant risk GI bleeding interferes absorption study drug Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>